CTOs on the Move

Bionano

www.bionano.com

 
At Bionano, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what`s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bionano.com
  • 9540 Towne Centre Drive Suite 100
    San Diego, CA USA 92121
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Joyn Bio

Probiotics for Plants, We design microbes for more sustainable agriculture.

Lutonix

Lutonix is a Maple Grove, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sony Biotechnology Inc

iCyt is a profitable, innovative, bioscience technology company that will contribute to its community by: delivering novel cell measurement and handling technologies that enable our clients to create important new healthcare and agriculture

Halo Labs

Halo Labs is all about particle analysis. We live to find particles, analyze them, count them, and help our customers characterize them to better their biopharmaceutical products.

Capsida

We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.